Carboplatin and Paclitaxel with or without Ombrabulin for recurrent ovarian cancer
Conditions
Recurrent Ovarian Cancer
What is the purpose of this trial?
The purpose of this study will compare the effects of ombrabulin to placebo (an inactive substance) with the standard chemotherapy (paclitaxel + carboplatin) in the treatment of your recurrent ovarian cancer. Ombrabulin is a research antivascular drug that has been given to more than 450 subjects in other studies with various solid tumor types. Ombrabulin disrupts the internal lining of small vessels in the body, preferentially vessels that belong to the tumor because they are not mature and therefore are more sensitive for destruction.Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Female
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Sanofi-Aventis
- Dates:
- February 2012
- Last Updated:
- Study HIC#:
- 1105008546
Clinicaltrials.gov ID: Yale2106243
